Sentences with phrase «efficacy of treatment for»

Furthermore healthcare costs were reduced by 10 per cent due to reduced ADHD effects, efficacy of treatment for mental disorders improved by 18 per cent and staff turnover was reduced.

Dr. Goldstein's got the research to prove the efficacy of this treatment for long - term health, happiness, and well - being.

The efficacy of these treatments for other anxiety disorders in children and adolescents has been supported by multiple randomized controlled trials (e.g., Walkup et al., 2008).

«The distinct neural markers associated with cognitive performance and GWI revealed in our study can be useful for future research to objectively measure the efficacy of treatments for GWI as well as other brain disorders related to the same neurotransmitter system, like Alzheimer's disease.»

The present research aims to determine whether choline intake also regulates an individual's risk for depression, associated outcomes, and the efficacy of treatments for it.

The clinical implications most relevant to the hypotheses are discussed, and to improve the efficacy of treatments for childhood aggression, it is proposed that anxiety may need to be the primary target of treatment.

Not exact matches

Rather, it's the no - holds - barred sales practices that Alexion allegedly engaged in — which, in some cases, reportedly led to salespeople bullying doctors into prescribing the drug for patients even when the efficacy of the treatment was unclear.

Insurers like Anthem have refused to cover the exorbitantly pricey treatment (around $ 300,000) since the drug's label admits that Exondys hasn't proved its efficacy, making the therapy a roll of the dice for payers and patients alike.

The treatment was approved for the devastating rare disease Duchenne muscular dystrophy but created major divisions within the FDA because it simply hadn't demonstrated a whole lot of efficacy, meaning the pricey therapy is essentially being subjected to a real - world clinical test.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Though many of these rewetting drops are available over the counter, many were known to cause only temporary relief from signs and symptoms or may not even be an effective treatment and some of these rewetting agents have not been tested for its efficacy scientifically.

For the same reason, it is not easy to prove treatment efficacy by means of controlled, randomized studies, the «gold standard» for evaluating new therapiFor the same reason, it is not easy to prove treatment efficacy by means of controlled, randomized studies, the «gold standard» for evaluating new therapifor evaluating new therapies.

Lack of efficacy of thickened feeding as treatment for gastroesophageal reflux.

Meta - analyses of studies evaluating these programs show positive effects on the competence, efficacy and psychological health of the parents, as well as on the behaviour of the children.49, 50 A recent implementation study of a strategy for parenting and family support showed that families in the treatment group had far fewer cases of substantiated child maltreatment, abuse injuries and out - of - home placements.51

«Until we have further evidence on the efficacy of medical cannabis for the treatment of sleep apnea, and until its safety profile is established, patients should discuss proven treatment options with a licensed medical provider at an accredited sleep facility,» said lead author Dr. Kannan Ramar, professor of medicine in the division of pulmonary and critical care medicine at Mayo Clinic in Rochester, Minnesota.

Researchers conclude that for the treatment of primary insomnia, neurofeedback does not have a specific efficacy beyond unspecific placebo effects.

There is no cure for HD and current treatments are of very limited efficacy.

Dr. Rassool says that a clinical trial is planned to test whether low doses of a DNMT inhibitor, decitabine, and an investigational PARP inhibitor, talazoparib, can be safely combined and whether this therapy shows efficacy for AML patients, especially those who can not receive intensive chemotherapy, whose leukemia is resistant to treatment, or who have experienced a relapse after treatment.

Schlom, of the National Cancer Institute, says the next challenge for researchers is to find ways to combine different immunotherapy drugs into single treatments and measure their efficacy in clinical trials.

These encouraging results in terms of safety and efficacy are paving the way for a new kind of treatment, not only for Still's disease, but other rare inflammatory diseases, too.

Prior studies on the diet have shown potential for alleviating symptoms of the neurodegenerative disease multiple sclerosis, increasing the efficacy of chemotherapy for cancer treatments, and decreasing visceral fat.

The estimation of EGFR mutation status is essential for the identification of non-small cell lung carcinoma (NSCLC) patients who may benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs), and hence for improving therapeutic efficacy.

Following a systematic review of case reports and an FDA safety database, researchers at the Perelman School of Medicine at the University of Pennsylvania are calling for formal controlled investigations into the safety and efficacy of off - label use of the Lariat device, which has never been approved for treatment of this condition.

«We hope that this assessment of the efficacy of currently available migraine therapies helps patients and their physicians utilize treatments that are the most appropriate for them,» said Dr. Silberstein.

Exploiting the same pre-clinical model used for their studies, the researchers are testing the efficacy of this kind of drug candidates against cancer stem cells, and the possibility of identifying combination regimens with standard chemotherapies with minimized toxic effects, with the perspective of their possible application for the treatment of human breast cancer.

This is intended to verify the efficacy of this treatment method, and to help ensure the implementation of dTMS for MS - associated fatigue into routine clinical practice.

The authors say: «The excellent efficacy of DP for the treatment of malaria in multiple countries and for chemoprevention in our high transmission area suggest that this regimen will offer benefit in many regions in need of improved control measures.»

Prof Fortunato Ciardiello from Seconda Università degli Studi di Napoli, Italy, presented results from the CAPRI - Goim study on the efficacy of cetuximab plus FOLFOX chemotherapy as second - line treatment for patients with mCRC that progressed following FOLFIRI chemotherapy and cetuximab.

«All endpoints of efficacy and tolerability favoured treatment with pembrolizumab, suggesting it should become one standard of care for first line treatment of patients with advanced NSCLC and high PD - L1 expression.

The goals of Cohort B, for which survival data are not yet complete, were, primarily, to prove pembrolizumab's safety and, secondarily, to explore its efficacy as a first - line treatment.

As a result, clinicians are able to make faster and better - informed assessments of a patient's condition, allowing treatment to be personalized for maximum efficacy.

In an efficacy study involving nonhuman primates that was specifically designed to evaluate the efficacy of AVI - 7288 after delayed treatment, a dose of 15 mg per kilogram per day for 14 days starting at 24, 48, and 96 hours after viral challenge provided 83 %, 100 %, and 83 % protection, respectively.

Additionally, the proportion of patients in the United States who are prescribed opioids for non-cancer pain has almost doubled over the past decade, indicating the need to do a more focused examination on the safety and efficacy of these and other treatment options.

Another treatment, intravenous injection of a clot - dissolving substance, has an even tighter AHA - recommended time limit for efficacy — 4.5 hours — and isn't very effective for treating large clots.

A clinical trial investigating a treatment for blindness is under way this winter to evaluate the safety and efficacy of replacing diseased eye cells with stem cells.

The technique used to assess addiction - like behavior in rats can also be used in humans, so if similar results are found in addicted people, the researchers hope the technique may help identify people most susceptible to addiction and be useful for predicting the efficacy of oxytocin treatment.

«Additional studies should certainly be considered, but we hope that medical professionals will consider the positive potential of honey as a treatment given the lack of proven efficacy, expense and potential for adverse effects associated with the use of DM,» said lead study author Ian Paul, a pediatrician and associate professor of pediatrics.

Although further research into A-CRA's efficacy in treating various combinations of substance use and psychiatric disorders is warranted, the authors argue that there's no reason for providers to wait when it comes to offering comprehensive treatment to adolescents who could benefit from their help right now.

The Phase 2/3 trials will be sponsored by Vtesse, a new biotech company that was formed specifically to evaluate the safety and efficacy of cyclodextrin for the treatment of NPC and ultimately obtain FDA labeling if the drug is effective.

A pooled analysis of data from two randomised trials comparing vitamin E versus placebo, and the placebo group from another trial comparing vitamin E use versus non-use, demonstrates that the efficacy of vitamin E is comparable to other treatments for NASH, including pioglitazone, metformin and obeticholic acid.

However, no data existed to compare the addition of these treatment approaches to usual medical care for OA or for the long - term efficacy of this holistic approach.

This knowledge may be used to develop new ways for opening the blood - brain - barrier to increase the efficacy of the brain cancer drugs and for the design of treatment regimes that strengthens the integrity of the blood - brain barrier.»

A total of 347 patients (155 treated with vitamin E, 192 not treated with vitamin E) were included in the analysis which compared data from three clinical trials that investigated the efficacy and safety of vitamin E as a treatment for NASH: the PIVENS, TONIC and FLINT trials.

Improved diagnostic tests are on the horizon, but we need huge efforts to increase their accuracy, use them for active case finding in the community, and eventually make them available in low income countries so as to inform treatment decisions and preserve the efficacy of any new antibiotic drugs for TB,» says lead author of the Commission Professor Keertan Dheda, University of Cape Town.

The results from our new study suggest that entinostat may enhance the anti-tumor efficacy of PD - 1 targeted therapy through MDSC targeting, potentially providing an effective combination treatment approach for patients with solid tumors, including lung and renal cell carcinoma.»

As the next step for this line of research, the investigators plan to expand to a larger prospective multicenter trial to further investigate the efficacy of the treatment in a larger sample of patients with dry AMD.

Researchers at Massachusetts Eye and Ear / Harvard Medical School and the University of Crete have conducted a phase I / II clinical trial investigating the efficacy of statins (cholesterol - lowering medications) for the treatment of patients with the dry form of age - related macular degeneration (AMD)-- the leading cause of blindness in the developed world.

After participating in an 8 - week baseline period followed by 12 weeks of brivaracetam treatment, patients became eligible for long - term follow - up to monitor the drug's efficacy and safety.

Following the end of the first trial, there will be two more — to test the treatment's efficacy — before it can be approved for commercial use on the market.

In an effort to tackle this rising challenge, researchers from Australia's National Institute of Complementary Medicine (NICM), Harvard Medical School, The University of Manchester, and the Black Dog Institute in Australia examined the efficacy of smartphone - based treatments for depression.